Silo Pharma Enters into Sponsored Research Agreement with the University of Maryland, Baltimore
July 15, 2021
Englewood Cliffs NJ, July 12, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO), a development stage biopharmaceutical company, today announced that it has entered into a Scientific Research Agreement with the University of Maryland, Baltimore. The main objective of our study is to evaluate the pharmacokinetics of dexamethasone... Read more
Clearmind Announces Changes To Senior Management As It Accelerates Development Of Its IP Portfolio
July 14, 2021
Ryan Allway July 14th, 2021 Psychedelics Industry Veteran Dr. Adi Zuloff-Shani Takes The Helm As CEO Toronto, Ontario–(Newsfile Corp. – July 14, 2021) – Clearmind Medicine Inc. (CSE: CMND) (“Clearmind” or the “Company“), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve... Read more
Ryan Allway July 13th, 2021 Psychedelics, Top News Calgary, Alberta – July 13, 2021. For Immediate Release – Medxtractor Corp. (“MedX” or the “Corporation”) (CSE: MXT, OTC:MXTTF) reports filing of a patent application at the United States Patent and Trademark Office (USPTO). MedX (CSE: MXT, OTC:MXTTF) reports that it... Read more
Ryan Allway July 9th, 2021 Psychedelics TORONTO, July 8, 2021 /CNW/ – Horizons ETFs Management (Canada) Inc. (“Horizons ETFs“) is announcing that Atai Life Sciences N.V. (“Atai Life Sciences“) has been included as a fast entry addition to the North American Psychedelics Index, (the “Index“), which is the underlying index of... Read more
MedXtractor Corp. (“MedX” or the “Corporation”) (CSE: MXT, OTC:MXTTF) Reports Share Sales by its Majority Shareholder
July 9, 2021
Ryan Allway July 9th, 2021 Psychedelics Calgary, Alberta – July 9, 2021. Medxtractor Corp. (“MedX” or the “Corporation”) (CSE: MXT, OTC:MXTTF) reports share sales by its majority shareholder. MedX (CSE: MXT, OTC:MXTTF) reports that it has been notified by it’s President and controlling shareholder James Durward, that he has... Read more
Ryan Allway July 8th, 2021 Psychedelics, Top News Enveric Enters into Clinical Stage Development of Lead Asset, EV101, in Israel with MOH Approval NAPLES, Fla., July 8, 2021 /PRNewswire/ — Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, announced... Read more
Ryan Allway July 7th, 2021 Psychedelics, Top News VANCOUVER, British Columbia, July 07, 2021 (GLOBE NEWSWIRE) — KetamineOne Capital Limited (“ Ketamine One ” or the “ Company ”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0) , a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased... Read more
Ryan Allway July 7th, 2021 Psychedelics TORONTO, July 07, 2021 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating optimized next-generation psychedelic medicines to treat neurological and neuropsychiatric disorders with unmet medical needs, today announced... Read more
Ryan Allway July 6th, 2021 Psychedelics, Top News Dr. Johnson’s primary area of research expertise is the psychopharmacology of medications for treating addictions, and he is well known in the field for his discovery that topiramate, a gamma-aminobutyric acid July 06, 2021 08:30 ET | Source: Ehave MIAMI, July 06, 2021... Read more
MedXtractor Fills a Key Gap in Mental Health Treatments
June 30, 2021
Ryan Allway June 30th, 2021 App, Exclusive, Psychedelics, Top News According to the Lancet Commission, mental health disorders are on the rise in every country worldwide, and the resulting lost productivity will cost the global economy $16 trillion by 2030. Yet, despite nearly two billion people with mental illness... Read more
